UroGen Pharma is a clinical stage biotechnology company with the goal of transforming local therapy for urological pathologies. The Company is focusing on the development of novel pharmaceutical solutions for several forms of non-muscle invasive urothelial cancer, including low-grade bladder cancer, carcinoma in-situ (CIS) bladder cancer and low-grade upper tract urothelial carcinoma (UTUC), an unmet medical need for which there are no FDA approved drugs. UroGen’s drug candidates may have the potential to replace the burdensome and costly surgical interventions and shift the use of local drug treatment from adjuvant to first line therapy.
| Website | http://www.urogen.com |
| Ticker | URGN |
| Revenue | $85 million |
| Funding | $75 million |
| Employees | 27 (7 on RocketReach) |
| Founded | 2005 |
| Address | 400 Alexander Park Dr Fl 4, Princeton, New Jersey 08540, US |
| Phone | (646) 768-9780 |
| Fax | +972 77-417-1410 |
| Industry | Pharmaceuticals, Biopharma, Drug Delivery, Non-Surgical Treatment, Healthcare, Biotechnology, Therapeutic Devices, Local Treatment, Health Care, Sustained Release Formulations, Science and Engineering, Bladder Cancer, Clinical Trials, Overactive Bladder, Life Science, Specialty Pharmaceutical, Pharmaceutical, UTUC, Interstitial Cystitis, Chemoablation, Immunotherapy |
| Web Rank | 8 Million |
| Keywords | Bladder Cancer Treatment, Clinical Stage Biopharmaceutical, Urological Oncology, Urology Research, Oncology Drug Development, Drug Development |
| Competitors | Roche, Pfizer, Amgen, Bristol Myers Squibb, AstraZeneca, Novartis, AbbVie, Astellas Pharma US, Sanofi, Merck AH +42 more (view full list) |
| SIC | SIC Code 283 Companies, SIC Code 28 Companies |
| NAICS | NAICS Code 5413 Companies, NAICS Code 3254 Companies, NAICS Code 54 Companies, NAICS Code 325 Companies, NAICS Code 541 Companies, NAICS Code 32 Companies, NAICS Code 54138 Companies, NAICS Code 32541 Companies |
Looking for a particular UroGen Pharma (formerly TheraCoat) employee's phone or email?
UroGen Pharma (formerly TheraCoat) Questions
The UroGen Pharma (formerly TheraCoat) annual revenue was $85 million in 2026.
Kristy Biswas is the Director, Key Accounts - Market Access of UroGen Pharma (formerly TheraCoat).
7 people are employed at UroGen Pharma (formerly TheraCoat).
UroGen Pharma (formerly TheraCoat) is based in Princeton, New Jersey.
The NAICS codes for UroGen Pharma (formerly TheraCoat) are [5413, 3254, 54, 325, 541, 32, 54138, 32541].
The SIC codes for UroGen Pharma (formerly TheraCoat) are [283, 28].
Top UroGen Pharma (formerly TheraCoat) Employees
-
Kristy Biswas
Director, Key Accounts - Market Access at UroGen Pharma (formerly TheraCoat)
New York, New York, United States23 -
Katherine Cilwa
Medical Director, Medical Affairs at UroGen Pharma (formerly TheraCoat)
Silver Spring, MD, US22
Related Companies
